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Supplementary File - Neurofilament light chain: a biomarker for genetic frontotemporal dementia 
Supplementary Methods 
Serum NfL concentrations were measured in duplicate by an earlier described, slightly modified, 
electrochemiluminescence (ECL) immunoassay with antibodies identical to those used in the CSF ELISA 
(Supplementary Methods).
1,2
 The ECL assay was slightly modified: coating was done with 0.05 M carbonate-
bicarbonate buffer (pH 9.6) at 4°C. Non-specific binding sites were blocked with 100 µl of TBS, containing 3% 
milk powder, per well for 1h. We used 25 µl of TBS containing 1% milk powder, 0.1% Tween 20 and 600/300 
µg/ml HeteroBlock® (Omega Biologicals, Bozeman, MT, USA) as sample diluent. Calibrators were prepared in 
TBS containing 1% milk powder, 0.1% Tween 20 and 300 µg/ml HeteroBlock®. Samples below the lowest standard 
but above the signal of the blank were extrapolated from the standard curve, otherwise assigned a concentration of 0 
pg/ml.
3
 Intermediate precision/repeatability were 6.1%/3.7%, respectively (sample with mean concentration 72.8 
pg/ml), 8.9%/7.1% (52.3 pg/ml) and 14.9%/9.8% (9.1 pg/ml) for the ECL assay.
4
 All sample CVs of duplicate 
measurements were below 20.0% (median 4.7%). 
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Supplementary Figures 
 
Supplementary Figure 1. Patient numbers per collected material and available MR-imaging. Displayed 
numbers are after exclusion of outliers. *Three subjects were excluded from the analysis on the correlation between 
serum and CSF because the interval between serum and CSF collection was longer than one year (1 control, 2 
presymptomatic carriers). 
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Supplementary Figure 2. NfL levels in presymptomatic carriers and controls. NfL levels in (A) CSF 
and (C) serum by controls and presymptomatic carriers.  Green dashed lines represent the cut-off line to 
separate controls from presymptomatic carriers at 1066 pg/ml for CSF (sensitivity 40%, specificity 94%) 
and at 8.3 pg/ml for serum (sensitivity 34%, specificity 97%). NfL levels in (B) CSF and (D) serum in 
controls and presymptomatic carriers specified by genetic group (GRN, C9orf72 and MAPT). Significances 
from the ANCOVA analyses are displayed (corrected for age). Association between (E) CSF NfL and (F) 
serum NfL and time from estimated onset in controls (red circles) and presymptomatic carriers (GRN filled 
blue triangles, C9orf72 filled blue squares, MAPT filled blue diamonds). One young individual is omitted 
from the graphs, but not from the analyses, to prevent disclosure of the genetic status. Presymptomatic 
carriers with CSF NfL values (n=9) and serum NfL values (n=14) of >2SD above the mean of controls were 
closer to or beyond the estimated onset (CSF mean 1,1 years and serum mean 0,8 years after estimated 
onset) than the presymptomatic carriers below that cut-off (CSF mean 10,2 years and serum 9,1 years to 
estimated onset, both p<0.001). In presymptomatic carriers, both CSF and serum NfL significantly 
correlated with time to onset or estimated onset (CSF rs=0.69, p<0.001 and serum rs=0.57, p<0.001). Ns, not 
significant. 
 
  
Meeter et al. Neurofilaments in genetic frontotemporal dementia 
 
 
 
Supplemental Figure 3. Square root transformed NfL levels in presymptomatic carriers and patients. Square 
root of NfL in (A) CSF and (C) serum by controls, presymptomatic carriers and patients. Additionally, square root 
of NfL levels in (B) CSF and (D) serum specified by genetic group and clinical stage. Significances from the 
ANCOVA analyses are displayed (corrected for age in all comparisons and additionally for disease duration in the 
comparisons between affected genes in patients). Ns, not significant; *, p≤0.05; **, p≤0.01; ***, p≤0.001. 
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Supplementary Figure 4. Correlation between CSF NfL and MR-imaging data. (A) Correlation of whole brain 
volume with CSF NfL in controls (red circles) and presymptomatic carriers (GRN blue filled triangles, C9orf72 blue 
filled squares, MAPT blue filled diamonds). Correlations between CSF NfL and (B) frontal lobe volume and (C) 
temporal lobes volume in presymptomatic carriers (blue squares) and patients (orange triangles).  
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Supplementary Figure 5. Longitudinal CSF NfL samples. Longitudinal samples of two converters (green and 
light blue lines), two presymptomatic carriers (dark blue lines) and one patient (orange line), plotted by time from 
onset or estimated onset in years. 
 
